Please login to the form below

Not currently logged in
Email:
Password:

Ashfield to establish European MSL network for Diurnal's Infacort

Hormone replacement drug anticipated to receive EU approval later this year
Ashfield Healthcare

Ashfield Commercial and Medical Services has been selected by hormone diseases specialist Diurnal to support the launch of its first product, Infacort (hydrocortisone).

Working with fellow UDG Healthcare company Sharp Packaging, Ashfield will begin pre-launch activities across Europe in anticipation of the chronic endocrine disease therapy's projected 2018 launch - the UK pharma firm having submitted Infacort for EMA approval in December last year.

Mark Gibson, director of international business at Ashfield, said: “We are delighted to be working with Diurnal on launching their products across key European markets.

“We will be able to support Diurnal in successfully launching treatments for chronic endocrine diseases and ultimately be able to make a difference to the lives of these patients.”

The pharma services provider will be responsible for building Diurnal's sales and medical infrastructure in several major EU markets, with the next 12 months focused on establishing a network of medical liaison staff to pave the way for the hormone replacement therapy.

Dr Martin Whitaker, chief executive of Diurnal, added: “We are confident the agreements with Ashfield and Sharp will help ensure the prompt and effective market introduction of Infacort following its anticipated approval in Europe.

“[The deals are] another key step in realising our ambition of becoming the world's leading specialty pharma company in endocrinology.”

Article by
Rebecca Clifford

30th January 2017

From: Marketing

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wordbird

Wordbird is a healthcare communications agency with creative, compelling copy at its heart....

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics